Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
Status:
Terminated
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if implitapide, used in conjunction with other
lipid-lowering therapies, is safe and effective when compared to placebo in lowering
low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial
hypercholesterolemia (HoFH).